Why Is Prescient Therapeutics (ASX:PTX) Stock Up 7% Today?

Sonal Goyal

22 October 2026 01:07 PM AEDT

Why Is Prescient Therapeutics (ASX:PTX) Stock Up 7% Today?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Prescient Therapeutics (ASX:PTX) shares were up 7.02% at $0.061 during the Trading session on 22 October 2026.
The PTX-100 Phase 2a CTCL study had 29 patients enrolled at 30 September 2026, and its first DOC review is due in December 2026.
Prescient raised about $6.0 million at $0.065 per share, with cash of $5.8 million at quarter end and a pro forma $11.8 million.

Prescient Therapeutics Ltd (ASX:PTX) shares were up 7.02% at $0.061 during the trading session on 22 October 2026, at 11:55 am. The S&P/ASX 200 stood at 8,774.90, down 0.64% (56.40 points), and the All Ordinaries at 8,897.80, down 0.66%, at the same time. Prescient is a clinical-stage oncology company developing targeted therapies and cell therapy enhancement platforms for cancer, led by its PTX-100 programme in cutaneous T-cell lymphoma.

About the Company

Prescient Therapeutics is headquartered in Melbourne, Australia, and trades on the ASX under the ticker PTX. The company describes itself as a clinical-stage oncology company developing personalised cancer treatments through targeted therapies and advanced cell therapy enhancement platforms. James McDonnell is Chief Executive Officer, and Dr Rosalind Wilson commenced as Chief Medical Officer on 13 July 2026, leading the Phase 2 study in cutaneous T-cell lymphoma (CTCL).

Business Overview

The lead asset, PTX-100, is described as a first-in-class compound that blocks the enzyme geranylgeranyl transferase-1 (GGTase-1), disrupting oncogenic Ras pathways and leading to cancer cell death. The company notes that Ras pathway mutations are believed to be involved in up to 22% of all cancers. The US FDA has granted PTX-100 Orphan Drug Designation for all T-cell lymphomas and Fast Track Designation for relapsed or refractory mycosis fungoides, the most common CTCL subtype. Prescient also holds two cell therapy platforms: OmniCAR, a universal immune receptor platform in preclinical development, and the CellPryme technologies.

PTX-100 Phase 2a Progress

In its September 2026 quarterly activities report dated 13 October 2026, Prescient said the Phase 2a study of PTX-100 in relapsed or refractory CTCL had reached its pre-specified enrolment threshold for the first Dose Optimisation Committee (DOC) review, with 20 evaluable patients, 10 in each of the two dosing arms. Patients are considered evaluable after four cycles of treatment. The DOC will convene in December 2026 to review safety and efficacy data and provide guidance on continuing the study. The company stated the review is a planned milestone of the dose optimisation design and not completion of the study.

Three patients were enrolled during the quarter, bringing total enrolment to 29 patients at 30 September 2026, compared with 26 at 30 June 2026. Prescient attributed the pace to the Northern Hemisphere summer slowdown. Enrolment continues towards a target of 40 evaluable patients, with sites in Australia, the United States and Italy and work under way to open sites in France.

Capital Raise and Cash Position

During the quarter Prescient completed a Share Purchase Plan that raised $4.8 million after final reconciliation, followed by a Placement of approximately $1.2 million, for a combined raise of about $6.0 million before costs. Both were priced at $0.065 per share, shares were allotted on 30 September 2026, and funds were received on 1 October 2026. The company said the proceeds will fund PTX-100 development beyond the first DOC review.

Cash at 30 September 2026 was $5.8 million, compared with $9.03 million at June 2026, or a pro forma $11.8 million including the raise. Net operating cash outflows totalled $3.2 million, including $1.98 million on research and clinical activities. Fees to non-executive directors totalled $80,000.

Related Sector Context

Clinical-stage oncology companies typically have no product Revenue and rely on Equity raising to fund trials, with progress measured through enrolment, committee reviews and data readouts. At 11:55 am on 22 October 2026 the S&P/ASX 200 was down 0.64% and the All Ordinaries down 0.66%, while Prescient shares were up 7.02% at the time of the data.

Risks to Weigh In

PTX-100 is in mid-stage development, and the December 2026 DOC review will assess safety and efficacy data from both dosing arms before any guidance on continuation. Enrolment towards 40 evaluable patients is still under way. Prescient reported net operating outflows of $3.2 million for the quarter and relies on external funding; the $6.0 million raise extends its position. The OmniCAR platform remains preclinical, and Business development discussions on OmniCAR and CellPryme have been described only as continuing, without a stated outcome or timeline.

Catalysts on Watch

The first DOC review is on track to convene in December 2026, and the company says it will update the market following the committee's recommendation. Enrolment is continuing towards the full target of 40 evaluable patients. After selecting a recommended Phase 2 dose for CTCL, the company will consider additional studies in peripheral T-cell lymphoma. Business development discussions on OmniCAR and CellPryme are continuing. An online investor briefing with CEO James McDonnell was scheduled for 21 October 2026.

Putting It Together

Prescient shares were up 7.02% at $0.061 during the 22 October 2026 session. The company's quarterly report, dated 13 October 2026, recorded 29 patients enrolled, a $6.0 million Capital raise priced at $0.065 and a first DOC review set for December 2026.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.